[1] Chen LYC, Mattman A, Seidman MA, et al. IgG4-related disease: what a hematologist needs to know [J]. Haematologica, 2019, 104(3):444-455. [2] Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD) 2011 [J]. Mod Rheumatol, 2012, 22(1):21-30. [3] Wallace ZS, Khosroshahi A, Carruthers MD, et al. An international multispecialty validation study of the IgG4-related disease responder index [J]. Arthritis Care Res (Hoboken), 2018, 70(11):1671-1678. [4] 钟宇,田芳,邹明宇,等.IgG4相关性疾病的影像学特征分析[J].中国医科大学学报,2019,48(10):939-943. [5] 张盼盼,张文.IgG-4相关性疾病脏器损伤的临床特点、影像学及病理特征[J].中华内科杂志,2016,55(8):657-661. [6] Wang L, Zhang P, Zhang X, et al. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients [J]. Rheumatology (Oxford), 2019,58(5): 820-830. [7] Sekiguchi H, Horie R, Kanai M, et al. IgG4-related disease: retrospective analysis of one hundred sixty-six patients [J]. Arthritis Rheumatol, 2016,68(9): 2290-2299. [8] Campochiaro C, Ramirez GA, Bozzolo EP, et al. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients [J]. Scand J Rheumatol, 2016,45(2):135-145. [9] Zhao Z, Wang Y, Guan Z, et al. Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases [J]. Clin Exp Rheumatol, 2016,34(1): 119-125. [10] Culver EL, Sadler R, Bateman AC, et al. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease [J]. Clin Gastroenterol Hepatol, 2017,15(9):1444-1452. [11] Moteki H, Yasuo M, Hamano H, et al. IgG4-related chronic rhinosinusitis: a new clinical entity of nasal disease [J]. Acta Otolaryngol, 2011,131(5):518-526. [12] Tanaka A, Moriyama M, Nakashima H, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease [J]. Arthritis Rheum, 2012,64(1):254-263. [13] Dong ZM, Lin E, Wechsler ME, et al. Pulmonary eosinophilic granulomatosis with polyangiitis has IgG4 plasma cells and immunoregulatory features [J]. Am J Pathol, 2020, 190(7):1438-1448. [14] Zhang X, Zhang P, Peng L, et al. Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease [J]. Clin Rheumatol, 2018, 37(12): 3387-3395. [15] Li KM, Xu MH, Wu X, et al. The expression of IgG and IgG4 in orbital MALT lymphoma: the similarities and differences of IgG4-related diseases [J]. Onco Targets Ther, 2020, 13:5755-5761. [16] Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease [J]. Clin Gastroenterol Hepatol, 2018,16(5):1947-1953. [17] Schirmer JH, Hoyer BF. IgG4-related disease [J]. Dtsch Med Wochenschr, 2019,144(24):1726-1730. [18] Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease [J]. Lancet, 2015, 385(9976):1460-1471. [19] Terao T, Yamamoto K, Ikeuchi K, et al. Hyper-IL-6 syndrome mimicking IgG4-related disease [J]. Rinsho Ketsueki, 2019, 60(5):392-397. [20] Tsuboi H, Honda F, Takahashi H, et al. Pathogenesis of IgG4-related disease. comparison with Sjögren's syndrome [J]. Mod Rheumatol, 2020, 30(1):7-16. [21] 李晓杰,邵博,刘慧,等.免疫球蛋白G4相关性涎腺炎12例临床特点分析[J].中华风湿病学杂志,2019,23(9):599-604. [22] Gupta A, Shareef M, Lade H, et al. Kimura's disease: A diagnostic and therapeutic challenge [J]. Indian J Otolaryngol Head Neck Surg, 2019, 71:855-859. [23] Blaho M, Dítē P, Kunovský L, et al. Autoimmune pancreatitis-An ongoing challenge [J]. Adv Med Sci, 2020, 65(2):403-408. [24] Sedassari BT, Dos Santos HT, Mariano FV, et al. Carcinoma expleomorphic adenoma of minor salivary glands with major epithelial-myoepithelial component: clinicopathologic and immunohistochemical study of 3 cases [J]. AnnDiagn Pathol, 2015, 19(3):164-168. [25] 赵厚亮,王文涛,王伟,等.CT纹理分析在腮腺多形性腺瘤与腺淋巴瘤鉴别诊断中的价值[J].口腔医学研究,2018,34(10):1127-1131. [26] Shirakashi M, Yoshifuji H, Kodama Y, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study [J]. Sci Rep, 2018, 8(1):10262. [27] 滕菲,张文.生物制剂在IgG4相关性疾病中的临床应用:现状与前景[J].中华临床免疫和变态反应杂志,2019,13(6):473-476. [28] Shimizu Y, Yamamoto M, Naishiro Y, et al. Necessity of early intervention for IgG4-related disease-delayed treatment induces fibrosis progression [J]. Rheumatology(Oxford), 2013, 52(4):679-683. |